Novo’s semaglutide superior to Lilly’s Trulicity in diabetes trial

Novo Nordisk’s once-weekly diabetes drug semaglutide has beaten Eli Lilly’s once-weekly therapy dulaglutide on reducing blood sugar and weight in patients taking part in a late-stage trial. In the 40-week, Phase IIIb study, semaglutide 0.5mg achieved a statistically significant and superior reduction in HbA1c of 1.5 percent versus 1.1 percent with 0.75mg dulaglutide (brand name Trulicity). Simliarly, those given the 1.0mg dose of semaglutide experienced a statistically significant and superior reduction in HbA1c of 1.8 percent compared with a decrease of 1.4 percent recorded for patients taking 1.5mg dulaglutide.